Mirum Pharmaceuticals
Mirum Pharmaceuticals' revenue rose 54.7% to $521 million in fiscal 2025. Its operating margin was −4.2%, up from −26.0% a year earlier. Free cash flow was $55 million, up 488.0%. The diluted share count rose 5.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Mirum Pharmaceuticals does
Mirum Pharmaceuticals develops and sells medicines for rare diseases. It has three approved medicines. Livmarli (maralixibat) is a pill that treats itching from bile flow problems (cholestatic pruritus) in people with Alagille syndrome and progressive familial intrahepatic cholestasis, two rare liver diseases. It is approved in the United States, the European Union and other countries. Cholbam (cholic acid) treats bile acid synthesis disorders, and Ctexli (chenodiol) treats cerebrotendinous xanthomatosis, a rare inherited disease.
Mirum sells Livmarli with its own commercial team in the U.S., Canada and some European countries. It has also signed license and distribution agreements with other rare-disease companies to sell Livmarli in additional countries. It is testing Livmarli for itching in other rare conditions in a study called EXPAND.
In August 2023 it bought the assets for Cholbam and chenodiol from Travere Therapeutics. It also has product candidates in development, including brelovitug.
Its biggest risks, as it describes them
- It may not be able to grow its marketing and sales capabilities, or keep needed rights from partners.
- It may not get or keep adequate coverage and reimbursement for its medicines.
- Its medicines may fail to win acceptance among doctors, patients and others.
- Its medicines face ongoing regulatory obligations that could bring added costs or penalties.
- Its product candidates need substantial clinical testing, and trial enrollment can be slow.
Income statement
Mirum Pharmaceuticals lost money in fiscal 2025: a net loss of $23 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 156 | 152 | 286 | 280 | 383 |
| Debt incl. finance leases | — | 0 | 306 | 308 | 310 |
| Net debt (negative means net cash) | — | −152 | 20 | 28 | −74 |
| Net debt to EBITDA | — | — | — | — | −34.9x |
| Debt to equity | — | 0.0x | 1.2x | 1.4x | 1.0x |
| Interest coverage | — | −8.2x | −7.2x | −6.1x | −1.5x |
| Current ratio | 3.9x | 2.9x | 4.5x | 3.1x | 2.7x |
| Quick ratio | 3.9x | 2.9x | 4.2x | 2.9x | 2.5x |
Cash flow
Projections
Project Mirum Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Mirum Pharmaceuticals says to expect
- Full year 2026: net product sales
Commercial: Raising Full-Year Net Product Sales Guidance to $715 Million to $720 Million
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $9.0 million of Mirum Pharmaceuticals shares on the open market, and 8 insiders sold $42.9 million, $25.8 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | Laura BregeDirector | Sold | 14,167 | $94.21 | $1.3 million | Form 4 |
| Sep 14, 2026 | Eric BjerkholtChief Financial Officer | Sold | 9,943 | $98.37 | $978,093 | Form 4 |
| Sep 2, 2026 | Jolanda HoweSVP, Global Controller | Sold plan | 658 | $100.00 | $65,800 | Form 4 |
| Sep 1, 2026 | Christopher PeetzChief Executive Officer, Director | Sold plan | 30,000 | $98.68 | $3.0 million | Form 4 |
| Aug 18, 2026 | Jolanda HoweSVP, Global Controller | Sold | 40,000 | $100.00 | $4.0 million | Form 4 |
| Aug 11, 2026 | Eric BjerkholtChief Financial Officer | Sold plan | 6,001 | $99.90 | $599,500 | Form 4 |
| Aug 10, 2026 | Christopher PeetzChief Executive Officer, Director | Sold plan | 20,000 | $98.92 | $2.0 million | Form 4 |
| Aug 3, 2026 | Jolanda HoweSVP, Global Controller | Sold plan | 1,840 | $105.29 | $193,734 | Form 4 |
| Jul 6, 2026 | Christopher PeetzChief Executive Officer, Director | Sold plan | 20,000 | $122.27 | $2.4 million | Form 4 |
| Jul 6, 2026 | Eric BjerkholtChief Financial Officer | Sold plan | 5,000 | $122.25 | $611,273 | Form 4 |
| Jul 1, 2026 | Jolanda HoweSVP, Global Controller | Sold plan | 2,721 | $120.00 | $326,520 | Form 4 |
| Jun 17, 2026 | Jolanda HoweSVP, Global Controller | Sold plan | 2,594 | $101.95 | $264,458 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 8 | 4 of 8 | 5 of 8 |
| Rule of 40 | 103.7% | 83.5% | 65.3% |
| Altman Z'' | −0.23 | −0.87 | 0.54 |
| Accruals ratio | −18.5% | −14.9% | −10.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 3 of 8 | 4 of 8 | 5 of 8 |
Compare
Put Mirum Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals | FY25 | 54.7% | −4.2% | 10.5% | −7.1% | −34.9x | 5 | |
| Travere Therapeutics | FY25 | 110.5% | −12.8% | — | — | — | 7 | Compare |
| OPKO Health | FY25 | −14.9% | −19.4% | −31.4% | −7.0% | — | 4 | Compare |
| Innoviva | FY25 | 14.7% | 39.8% | 47.6% | 17.9% | — | 6 | Compare |
| Ardelyx | FY25 | 22.1% | −10.1% | −10.8% | −36.1% | — | 2 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | 0 | 19 | 77 | 186 | 337 | 521 |
| Revenue growth | — | — | — | 302.7% | 141.8% | 80.8% | 54.7% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 43 | 82 | 131 | 107 | 103 | 141 | 186 |
| Operating income | −55 | −104 | −173 | −131 | −109 | −88 | −22 |
| Net income | −53 | −103 | −84 | −136 | −163 | −88 | −23 |
| Diluted EPS (US$) | −4.58 | −4.09 | −2.77 | −4.02 | −4.00 | −1.85 | −0.47 |
| Diluted shares (millions) | 12 | 25 | 30 | 34 | 41 | 48 | 50 |
| Cash flow | |||||||
| Cash from operations | −39 | −89 | −133 | −120 | −71 | 10 | 56 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Free cash flow | −40 | −89 | −133 | −120 | −71 | 9 | 55 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 213 | 0 | 0 |
| Stock-based compensation | 6 | 13 | 23 | 27 | 35 | 48 | 71 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 117 | 232 | 156 | 152 | 286 | 280 | 383 |
| Debt incl. finance leases | — | — | — | 0 | 306 | 308 | 310 |
| Total assets | 147 | 241 | 295 | 353 | 647 | 671 | 843 |
| Total liabilities | 16 | 69 | 174 | 211 | 398 | 445 | 528 |
| Shareholders' equity | 130 | 172 | 120 | 142 | 249 | 226 | 315 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | — | — | −906.1% | −170.3% | −58.6% | −26.0% | −4.2% |
| Net margin | — | — | −438.9% | −176.1% | −87.7% | −26.1% | −4.5% |
| Free cash flow margin | — | — | −693.8% | −156.3% | −38.1% | 2.8% | 10.5% |
| Rule of 40 (growth + FCF margin) | — | — | — | 146.4% | 103.7% | 83.5% | 65.3% |
| Return on capital | — | — | — | — | −66.6% | −26.5% | −7.1% |
| Return on equity | — | −68.3% | −57.5% | −103.5% | −83.7% | −37.1% | −8.7% |
| Return on assets | — | −53.3% | −31.4% | −41.9% | −32.7% | −13.3% | −3.1% |
| Net debt to EBITDA | — | — | — | — | — | — | −34.9x |